NCT06168461 Daily Aspirin Treatment After Preeclampsia
| NCT ID | NCT06168461 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Anna Stanhewicz, PhD |
| Condition | Preeclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2023-11-01 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Eligibility Criteria
Inclusion Criteria: * had preeclampsia in the past 5 years, * 18 years or older Exclusion criteria: * current daily aspirin use, * skin diseases, * current tobacco or nicotine use (including vaping), * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * currently pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs, * bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06168461 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06168461 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06168461 currently recruiting?
Yes, NCT06168461 is actively recruiting participants. Contact the research team at anna-stanhewicz@uiowa.edu for enrollment information.
Where is the NCT06168461 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT06168461 clinical trial?
NCT06168461 is sponsored by Anna Stanhewicz, PhD. The trial plans to enroll 40 participants.